Skip to content

Cancers & treatments

News & evidence

Living with cancer

Learn & contribute

Loading

A public, cited, editable map of oncology: technologies, targets, products, companies, institutions, pathways, trials, pairings, roadmaps, and ideas. One page per object, with a plain-language TL;DR on every page.

Work in progress. Every fact on this site is being built and checked in the open and may be incomplete, out of date, or wrong. You must do your own research and verify anything here at its primary source before relying on it. Nothing on this site is medical advice; decisions belong with you and your clinicians.

OnCo is an information resource, not medical advice. Nothing here replaces a conversation with a qualified clinician. Never delay care because of something you read here; in an emergency, call your local emergency services. Terms of use

Browse by cancer
Tags
Search
Connections
For me
Navigator
Biomarker matrix
Calculators
Interactions
Decision aids
Checkpoint side effects
Tumour board
Compare
Counts by category
Rankings
Timeline
Year by year
Query builder
Graph explorer
Saved
Body map

Cancers & treatments

News & evidence

Institutions & people

Institutions
Universities
Trial leadership
People
Heroes and heroines
Companies
Startups
Requests for startups
Investors
Company scorecards
Trial sponsors
Manufacturing map
Countries
United States deep dive
India deep dive
China deep dive
Germany deep dive
Israel deep dive
United Kingdom deep dive
Cases by country
Funding flows

Living with cancer

For me
The first 60 days
Appointment prep pack
Side effects
Symptom to test
Report reader
Survivorship planner
Second opinion
Financial help
Free in oncology
Paying for care in the US
NHS coverage
Paying for care in India
Coverage rankings
Cutting cancer care costs
Diet, exercise and lifestyle
Supportive care
Recovery and rejuvenation
Complementary and supportive approaches
Hair loss and regrowth
What comes back after treatment
Heroes and heroines

Learn & contribute

Reading paths
About & methodology
Roadmap
Gaps to fill
Coverage of the field
Review queue
Reviewer roster
Contributors
Idea votes
Teaching packs
Weekly issue
Suggest an edit
Answer quality
Data dictionary
Build on OnCo
Open API
Open data
Open tools
Open source in oncology
The software of oncology
GitHub

© 2026 OnCo. Code MIT. The data are free for individual and educational use with the attribution “Data from OnCo (onco.cc)”, under CC BY-NC 4.0. Commercial use must contact us to pay for the data. Commercial licences. Made with heart and soul by Jude Gomila .

About and methodology Corrections Open API Tags Terms of use Privacy policy GitHub

Loading

Home
Cancers
HR-positive metastatic breast cancer after CDK4/6 inhibitors
What changed

HR-positive metastatic breast cancer after CDK4/6 inhibitors

What changed: HR-positive metastatic breast cancer after CDK4/6 inhibitors

Cancer page →

Every dated change on the records linked to HR-positive metastatic breast cancer after CDK4/6 inhibitors, newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.

Overview Types and stages Symptoms and diagnosis Treatment Trials and papers Biology and targets Countries and centres Decisions and support Pipeline and open problems Data

Trial result14Milestone7This record1On Edge

FollowWatch this cancer and Saved shows what changed since you last looked.Follow by feed

September 2026 · 1

2026-09-17This recordHR-positive metastatic breast cancer after CDK4/6 inhibitors
Facts on this page last checked
When this page itself was last checked or edited.

2026 · 1

2026MilestoneVepdegestrant
Vepdegestrant, the first PROTAC, approved
A milestone in how this cancer is treated.

2025 · 3

2025Trial resultevERA
evERA reported
PFS HR 0.
2025Trial resultSERENA-6
SERENA-6 reported
PFS 16.
2025MilestoneSERENA-6
SERENA-6: switch to camizestrant on circulating tumour DNA; imlunestrant approved (EMBER-3)
A milestone in how this cancer is treated.

2024 · 4

2024Trial resultDESTINY-Breast06
DESTINY-Breast06 reported
PFS HR 0.
2024Trial resultEMBER-3
EMBER-3 reported
PFS HR 0.
2024Trial resultpostMONARCH
postMONARCH reported
PFS 6.
2024MilestoneINAVO120
Inavolisib approved in the first line for PIK3CA-mutant relapse (INAVO120)
A milestone in how this cancer is treated.

2023 · 3

2023Trial resultINAVO120
INAVO120 reported
PFS 15.
2023Trial resultTROPION-Breast01
TROPION-Breast01 reported
PFS HR 0.
2023MilestoneEMERALD
Elacestrant (EMERALD) and capivasertib (CAPItello-291) approved
A milestone in how this cancer is treated.

2022 · 2

2022Trial resultCAPItello-291
CAPItello-291 reported
PFS HR 0.
2022Trial resultTROPiCS-02
TROPiCS-02 reported
OS 14.

2021 · 1

2021Trial resultEMERALD
EMERALD reported
PFS HR 0.

2019 · 1

2019MilestoneSOLAR-1
Alpelisib approved for PIK3CA-mutant disease (SOLAR-1)
A milestone in how this cancer is treated.

2018 · 2

2018Trial resultEMBRACA
EMBRACA reported
PFS 8.
2018Trial resultSOLAR-1
SOLAR-1 reported
PFS 11.

2017 · 1

2017Trial resultOlympiAD
OlympiAD reported
PFS 7.

2013 · 1

2013MilestoneHR-positive metastatic breast cancer after CDK4/6 inhibitors
ESR1 ligand-binding domain mutations found as the cause of acquired endocrine resistance
A milestone in how this cancer is treated.

2012 · 2

2012Trial resultBOLERO-2
BOLERO-2 reported
Everolimus plus exemestane more than doubled progression-free survival compared with exemestane alone; approved in July 2012.
2012MilestoneEverolimus
BOLERO-2: everolimus with exemestane after an aromatase inhibitor
A milestone in how this cancer is treated.